Cardiac steroidogenesis and glucocorticoid in the development of cardiac hypertrophy during the progression to heart failure

Journal of Hypertension

Volumn 27, Issue 5, 2009, Pages 1074-1083

  Ohtani, Tomohito ^a,b   Mano, Toshiaki ^a,b   Hikoso, Shungo ^a   Sakata, Yasushi ^a   Nishio, Mayu ^a,b   Takeda, Yasuharu ^a,b   Otsu, Kinya ^a   Miwa, Takeshi ^b   Masuyama, Tohru ^c   Hori, Masatsugu ^a   Yamamoto, Kazuhiro ^a,d  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

^d OSAKA UNIVERSITY   (Japan)

Author keywords

Glucocorticoid; Heart failure; Hormones; Hypertrophy

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CORTICOSTERONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; MINERALOCORTICOID RECEPTOR; MYOSIN HEAVY CHAIN ALPHA; PHENYLEPHRINE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA SURGERY; ARTICLE; BODY WEIGHT; CELL STRUCTURE; CELL SURFACE; CONTROLLED STUDY; DIET; DISEASE COURSE; GENE OVEREXPRESSION; HEART FAILURE; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; HEAVY CHAIN; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RAT; STEROIDOGENESIS;

EID: 62649120306     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328326cb04     Document Type: Article

References (33)

1. Guder G, Bauersachs J, Frantz S, Weismann D, Allolio B, Ertl G, et al. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation 2007; 115:1754-1761.
2. Katz SE, Penefsky ZJ, McGinnis MY. Cytosolic glucocorticoid receptors in the developing rat heart. J Mol Cell Cardiol 1988; 20:323-328.
3. Sheppard KE, Autelitano DJ. 11 Beta-hydroxysteroid dehydrogenase 1 transforms 11-dehydrocorticosterone into transcriptionally active glucocorticoid in neonatal rat heart. Endocrinology 2002; 143:198-204.
4. Ohtani T, Ohta M, Yamamoto K, Mano T, Sakata Y, Nishio M, etal. Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: beneficial effects of mineralocorticoid receptor blocker. Am J Physiol 2007; 292:R946-R954.
5. Muiesan ML, Lupia M, Salvetti M, Grigoletto C, Sonino N, Boscaro M, et al. Left ventricular structural and functional characteristics in Cushing's syndrome. J Am Coll Cardiol 2003; 41:2275-2279.
6. Sato A, Funder JW. High glucose stimulates aldosterone-induced hypertrophy via type I mineralocorticoid receptors in neonatal rat cardiomyocytes. Endocrinology 1996; 137:4145-4153.
7. Gardner DG, Gertz BJ, Deschepper CF, Kim DY. Gene for the rat atrial natriuretic peptide is regulated by glucocorticoids in vitro. J Clin Invest 1988; 82:1275-1281.
8. Shields PP, Dixon JE, Glembotski CC. The secretion of atrial natriuretic factor-(99-126) by cultured cardiac myocytes is regulated by glucocorticoids. J Biol Chem 1988; 263:12619-12628.
9. Lister K, Autelitano DJ, Jenkins A, Hannan RD, Sheppard KE. Cross talk between corticosteroids and alpha-adrenergic signalling augments cardiomyocyte hypertrophy: a possible role for SGK1. Cardiovasc Res 2006; 70:555-565.
10. Stocco DM. The role of the StAR protein in steroidogenesis: challenges for the future. J Endocrinol 2000; 164:247-253.
11. Kayes-Wandover KM, White PC. Steroidogenic enzyme gene expression in the human heart. J Clin Endocrinol Metab 2000; 85:2519-2525.
12. Young MJ, Clyne CD, Cole TJ, Funder JW. Cardiac steroidogenesis in the normal and failing heart. J Clin Endocrinol Metab 2001; 86:5121-5126.
13. Nakamura S, Yoshimura M, Nakayama M, Ito T, Mizuno Y, Harada E, et al. Possible association of heart failure status with synthetic balance between aldosterone and dehydroepiandrosterone in human heart. Circulation 2004; 110:1787-1793.
14. Doi R, Masuyama T, Yamamoto K, Doi Y, Mano T, Sakata Y, et al. Development of different phenotypes of hypertensive heart failure: systolic versus diastolic failure in Dahl salt-sensitive rats. J Hypertens 2000; 18:111-120.
15. 2+ affinity mutant of SERCA2a attenuates in vivo pressure overload cardiac hypertrophy. FASEB J 2003; 17:61-63.
16. Gulick J, Subramaniam A, Neumann J, Robbins J. Isolation and characterization of the mouse cardiac myosin heavy chain genes. J Biol Chem 1991; 266:9180-9185.
17. Sakata Y, Yamamoto K, Mano T, Nishikawa N, Yoshida J, Nakayama H, etal. Angiotensin II type 1 receptor blockade prevents diastolic heart failure through modulation of Ca(2b) regulatory proteins and extracellular matrix. J Hypertens 2003; 21:1737-1 745.
18. Yamamoto K, Masuyama T, Sakata Y, Doi R, Ono K, Mano T, et al. Local neurohumoral regulation in the transition to isolated diastolic heart failure in hypertensive heart disease: absence of AT1 receptor downregulation and 'overdrive' of the endothelin system. Cardiovasc Res 2000; 46:421-432.
19. Nishikawa N, Yamamoto K, Sakata Y, Mano T, Yoshida J, Miwa T, et al. Differential activation of matrix metalloproteinases in heart failure with and without ventricular dilatation. Cardiovasc Res 2003; 57:766-774.
20. 2+ ATPase and decreasing phospholamban expression. J Mol Cell Cardiol 1994; 26:1145-1154.
21. Hirotani S, Otsu K, Nishida K, Higuchi Y, Morita T, Nakayama H, et al. Involvement of nuclear factor-kappaB and apoptosis signal-regulating kinase 1 in G-protein-coupled receptor agonist-induced cardiomyocyte hypertrophy. Circulation 2002; 105:509-515.
22. Nishikawa N, Masuyama T, Yamamoto K, Sakata Y, Mano T, Miwa T, et al. Long-term administration of amlodipine prevents decompensation to diastolic heart failure in hypertensive rats. J Am Coll Cardiol 2001; 38:1539-1545.
23. Nishio M, Sakata Y, Mano T, Yoshida J, Ohtani T, Takeda Y, et al. Therapeutic effects of angiotensin II type 1 receptor blocker at an advanced stage of hypertensive diastolic heart failure. J Hypertens 2007; 25:455-461.
24. Casal AJ, Silvestre JS, Delcayre C, Capponi AM. Expression and modulation of steroidogenic acute regulatory protein messenger ribonucleic acid in rat cardiocytes and after myocardial infarction. Endocrinology 2003; 144:1861-1868.
25. Sakata Y, Masuyama T, Yamamoto K, Doi R, Mano T, Kuzuya T, et al. Renin angiotensin system-dependent hypertrophy as a contributor to heart failure in hypertensive rats: different characteristics from renin angiotensin system-independent hypertrophy. J Am Coll Cardiol 2001; 37:293-299.
26. Kim S, Yoshiyama M, Izumi Y, Kawano H, Kimoto M, Zhan Y, et al. Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure. Circulation 2001; 103:148-154.
27. Silvestre JS, Robert V, Heymes C, Aupetit-Faisant B, Mouas C, Moalic JM, et al. Myocardial production of aldosterone and corticosterone in the rat. J Biol Chem 1998; 273:4883-4891.
28. Silvestre JS, Robert V, Escoubet B, Heymes C, Oubenaissa A, Desopper C, et al. Different regulation of cardiac and renal corticosteroid receptors in aldosterone-salt treated rats: effect of hypertension and glucocorticoids. J Mol Cell Cardiol 2000; 32:1249-1263.
29. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341:709-717.
30. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309-1321.
31. Funder JW. RALES, EPHESUS and redox. J Steroid Biochem Mol Biol 2005; 93:121-125.
32. Yamamoto K, Masuyama T, Sakata Y, Nishikawa N, Mano T, Yoshida J, et al. Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart. Cardiovasc Res 2002; 55:76-82.
33. Yamamoto K, Mano T, Yoshida J, Sakata Y, Nishikawa N, Nishio M, et al. ACE inhibitor and angiotensin II type 1 receptor blocker differently regulate ventricular fibrosis in hypertensive diastolic heart failure. J Hypertens 2005; 23:393-400.